Universal Access and Affordable Medicines
Our campaign promotes transparency, accountability and the public interest in the field of pharmaceuticals. Our evidence-based advocacy aims to guarantee better and affordable medicines for Europe by questioning and reforming the current pharmaceutical business model and calling for better access to medicines for all.
About our work on access to medicines
Publications
EPHA Position on Medicine Shortages
EPHA Response to public consultation on EMA Regulatory Science to 2025
BeNeLuxA et al.: the best is yet to come
Latest Developments
New civil society roadmap to improve treatment of children and rare diseases
Recommendations for the revision of EU legislation on medicines for childhood and rare diseases from EPHA, ECL, SIOPE and the European Fair Pricing Network
HERA should be independent and autonomous with a clear public health mission, EPHA says
HERA should be independent and autonomous with a clear public health mission, EPHA says in its response to the European Commission’s consultation
Increasing our options for cancer treatment in Europe
EPHA member, the Anticancer Fund calls for more research into repurposing of drugs to support cancer patients
Analysis & Opinion
The need for a healthy and robust civil society in shaping medicines’ policies in Europe
The access to medicines debate in Europe is at a critical juncture. With the pandemic, all issues, old and new, suddenly find a place on the agenda. They range from the prices of medicines, the flexibility of regulatory standards, the quality of...
The politicisation of pharma and medicines’ policies in Europe
The politicisation of pharma and medicines’ policies in Europe
Advocate sharing of patents, know-how, and technology to maximize vaccine production
How to maximise COVID-19 vaccine production.
Events
EPHA #A2MDialogues
A new series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.
Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.
Find out more and register for the latest discussion below
The Oslo Medicines Initiative: a new social contract with pharma
15 June 2021 | 13:00-14:00 CEST
A discussion with the WHO Regional Office for Europe and the Norwegian Medicines Agency about their new initiative to rebalance the relationship between governments, pharma and patients
Negotiating with pharma: lessons from the EU COVID-19 vaccine negotiations
18 May 2021
Sustainable access to effective antibiotics - what should the EU do?
15 April 2021
After COVID-19, what's next for EU medicines policies?
9 March 2021
Get monthly updates on key public health issues!
Past Events
Time for a new deal
14 November 2019
4th EPHA Universal Access and Affordable Medicines Forum. Challenging the status quo on medicines policy.
Putting health first
3 June 2019
Trailblazers, routes to better and affordable medicines by 2025
20 November 2018
How good are our medicines?
3 October 2018
Game changers for better and affordable medicines in Europe
21 November 2017
At the European Health Forum Gastein
How good are our medicines? An operational agenda for EU & national policy-makers
Medicines: new games, new rules - Pathways to better and affordable medicines.
“Healthy" innovation: putting patients before profits
Questions?
Meet our Universal Access and Affordable Medicines Policy Lead.
Yannis Natsis
Policy Manager
yannis@epha.org
+32 2 233 3886
